الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

teva b.v. - ribavirin - hepatit c, kronisk - antivirala medel för systemisk användning - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 och 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 och 5.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

rph pharmaceuticals ab - fenytoin - tablett - 100 mg - laktosmonohydrat hjälpämne; fenytoin 100 mg aktiv substans - fenytoin

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

leyh pharma gmbh - trihexyfenidylhydroklorid - tablett - 2 mg - trihexyfenidylhydroklorid 2 mg aktiv substans; laktosmonohydrat hjälpämne - trihexyfenidyl

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

karo pharma ab - bendroflumetiazid; kaliumklorid - filmdragerad tablett - 1,25 mg/573 mg - kaliumklorid 573 mg aktiv substans; stearylalkohol hjälpämne; glycerol hjälpämne; bendroflumetiazid 1,25 mg aktiv substans - bendroflumetiazid och kalium

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

teva b.v.  - lamivudin - hiv-infektioner - antivirala medel för systemisk användning - lamivudin teva pharma b. indikeras som en del av antiretroviral kombinationsbehandling för behandling av humana immunbristvirus (hiv) -infekterade vuxna och barn.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

panpharma sa - midazolam - injektionsvätska, lösning - 1 mg/ml - midazolam 1 mg aktiv substans - midazolam

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptika, - epilepsypregabalin mylan läkemedel är indicerat som tilläggsbehandling för vuxna med partiella anfall med eller utan sekundär generalisering. generaliserad Ångest disorderpregabalin mylan pharma är indicerat för behandling av generaliserat ångestsyndrom (gad) hos vuxna.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

mitsubishi pharma europe ltd - colestilan - hyperfosfatemi - läkemedel för behandling av hyperkalemi och hyperfosfatemi - behandling av hyperfosfatemi hos vuxna patienter med kronisk njursjukdom stadium 5 som får hemodialys eller peritonealdialys.